All New issues
Desjardins Canadian Financial Groups Principal Protected Notes, Series 218
$1.00;
- Principal Protected Notes
Additional Informations
| Issuer: | Fédération des caisses Desjardins du Québec |
|---|---|
| Securities Offered: | Desjardins Canadian Financial Groups Principal Protected Notes, Series 218 |
| Issue Price: | $ 100 per note |
| Minimum: | $ 1,000 (10 Notes) |
| Reference Index: | The reference basket is an equally weighted portfolio of common shares issued by 8 companies. La Financière Sun Life Inc., Banque Nationale du Canada, Intact Corporation financière, La Financière Manuvie, Banque Canadienne Impériale de Commerce, Banque de Montréal, Banque Royale du Canada, Banque de Nouvelle-Écosse |
| Issuance Date: | March 7, 2025 |
| Maturity Date: | March 5, 2032 |
| Settlement date: | Transaction date plus 2 days. **All purchases are closed without the possibility of cancellation ** Please refer to Information Statement Document, Right of cancellation. |
| RRSP & TFSA Eligibility: | Yes |
| Term: | 6 year(s), 11 month(s) and 27 day(s) |
| Participation Rate: | Participation rate of 125.00% |
| Maximum Return: | No cap is fixed as to the return of the Notes. |
| Principal Protected: | The capital is 100% guaranteed at maturity. |
| Early Trading Charge: | This fee goes from 4.25 %, initially to 0% after 450 days. |
| Secondary Market: | DSN01011 |
| Commission received from the Issuer: | Desjardins online brokerage will receive from the issuer a remuneration of $3.50 for each note sold (equivalent to 3.50 % of the principal amount) |
| Subscription close: | February 28, 2025, noon. Books can close without any further notice |
| Offering Document: | For more detailed information please refer to the prospectus. |
| Investment highlights: | To view the Investment highlights please refer to this document. |
The content of this page is transmitted strictly for informational purposes. Investments must be selected in accordance with the investor's respective objectives. Desjardins Online Brokerage does not issue any recommendations or endorsements concerning any particular product, its potential value or appropriateness, or any specific strategy. It is highly recommended to read the prospectus before making any type of investment.